Advertisement

Modern Rheumatology

, Volume 23, Issue 4, pp 709–715 | Cite as

Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide

  • Han-Gyul Yoo
  • Hea Min Yu
  • Jeon Byung Jun
  • Hyun-Soon Jeon
  • Wan-Hee YooEmail author
Original Article
  • 361 Downloads

Abstract

Objectives

To determine the risk of severe infection requiring or complicating hospitalization associated with leflunomide therapy in patients with rheumatoid arthritis (RA).

Methods

We performed a retrospective study of RA patients who were prescribed leflunomide between 2004 and 2011. Background clinical and laboratory features were compared between patients who suffered severe leflunomide-associated infections and those who did not.

Results

Since January 2005, 401 RA patients have started on leflunomide. Among those, 33 (8.2 %) developed severe infections: pneumonia, oral candidiasis, pyelonephritis, pulmonary tuberculosis, cellulitis, disseminated herpes zoster, tonsillitis, and pulmonary cryptococcosis. Logistic regression showed that age at entry, the presence of DM, and daily dosage of corticosteroid were associated with development of severe infections.

Conclusions

These results showed that some patients with RA who were taking leflunomide developed severe infections requiring hospitalization, and that older age, DM, and a higher daily dosage of corticosteroid were risk factors associated with leflunomide-associated severe infections.

Keywords

Infection Leflunomide Rheumatoid arthritis 

Notes

Conflict of interest

None.

References

  1. 1.
    Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med. 1953;249:553–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM 3rd, Therneau TM, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56:3583–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol. 2004;69:3–8.Google Scholar
  4. 4.
    Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol. 1999;162:2095–102.PubMedGoogle Scholar
  6. 6.
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999;353:259–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.PubMedCrossRefGoogle Scholar
  9. 9.
    Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, American College of Rheumatology, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.PubMedCrossRefGoogle Scholar
  10. 10.
    Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:987–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 1991;18:188–94.PubMedGoogle Scholar
  13. 13.
    van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994;53:224–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–300.PubMedCrossRefGoogle Scholar
  15. 15.
    van Albada-Kuipers GA, Linthorst J, Peeters EA, Breedveld FC, Dijkmans BA, Hermans J, et al. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum. 1988;31:667–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Caldwell JR, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum. 1991;21:1–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse effects. Am J Med. 1994;96:115–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Segal BH, Sneller MC. Life-threatening complications of autoimmune disease: infections complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am. 1997;23:220–37.CrossRefGoogle Scholar
  19. 19.
    Jenks KA, Stamp LK, O’Donnell JL, Savage RL, Chapman PT. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34:2201–3.PubMedGoogle Scholar
  20. 20.
    Savage RL, Highton J, Boyd IW, Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J. 2006;36:162–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Grover R, Dhir V, Aneja R, Arya V, Galle A, Marwaha V, et al. Severe infections following leflunomide therapy for rheumatoid arthritis. Rheumatology (Oxford). 2006;45:918–20.CrossRefGoogle Scholar
  22. 22.
    Bruyn GA, Jansen TL, Ten Brinke A, De Vries M, Houtman PM, van Roon EN. Cavitating pneumonia, a severe complication of leflunomide therapy in chronic polyarthritis. Rheumatology (Oxford). 2007;46:553–4.CrossRefGoogle Scholar
  23. 23.
    Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34:706–11.PubMedGoogle Scholar
  24. 24.
    Binymin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2001;40:341–2.CrossRefGoogle Scholar
  25. 25.
    Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum. 1995;24:411–21.PubMedCrossRefGoogle Scholar
  26. 26.
    Hernández-Cruz B, Sifuentes-Osornio J, Ponce-de-León Rosales S, Ponce-de-León Garduño A, Díaz-Jouanen E. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol. 1999;17:289–96.Google Scholar
  27. 27.
    Uddin J, Kraus AS, Kelly HG. Survivorship and death in rheumatoid arthritis. Arthritis Rheum. 1970;13:125–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Abruzzo JL. Rheumatoid arthritis and mortality. Arthritis Rheum. 1982;25:1020–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol. 1984;11:158–61.PubMedGoogle Scholar
  30. 30.
    Cosh JA. Survival and death in rheumatoid arthritis. J Rheumatol. 1984;11:117–9.PubMedGoogle Scholar
  31. 31.
    Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Otsuka T, Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology, et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1265–8.CrossRefGoogle Scholar

Copyright information

© Japan College of Rheumatology 2012

Authors and Affiliations

  • Han-Gyul Yoo
    • 1
  • Hea Min Yu
    • 2
  • Jeon Byung Jun
    • 2
  • Hyun-Soon Jeon
    • 2
  • Wan-Hee Yoo
    • 2
    Email author
  1. 1.Department of Pharmacy PracticeUniversity of Rhode IslandKingstonUSA
  2. 2.Division of Rheumatology, Department of Internal MedicineChonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University Hospital, Chonbuk National UniversityJeonjuSouth Korea

Personalised recommendations